Adherence to long-term use of renin-angiotensin II-aldosterone system inhibitors in children with chronic kidney disease

BMC Pediatrics
Chien-Ning HsuYou-Lin Tain

Abstract

Although renin-angiotensin II-aldosterone system inhibitor (RASI) use for renal protection is well-documented, adherence to RASI therapy in the pediatric population is unclear. This study aimed to evaluate patient characteristics associated with adherence to chronic RASI use in patients with childhood chronic kidney disease (CKD). Childhood CKD was identified using ICD-9 codes in the population-based, Taiwan national health insurance research database between 1997 and 2011. Patients continuously receiving RASIs for ≥3 months without interruption > 30 days after CKD diagnosis were defined as incident users. Medication adherence was measured as the proportion of days covered (PDC) by RASI prescription refills during the study period. Multivariate logistic regression was employed to assess the odds for adherence (PDC ≥80%) to RASI refills. Of 1271 incident users of RASI chronic therapy, 16.9% (n = 215) had PDC ≥80%. Compared to the group with PDC < 80%, patients in the high adherence group more often had proteinuria (aOR [adjusted odds ratio]1.93; 95%CI [confidence interval], 1.18-3.17), anemia (aOR, 1.76; 95% CI, 1.20-2.58), and time to start of chronic use > 2 years (aOR, 1.12; 95%CI, 1.06-1.19). Odds of being non-adherent were ...Continue Reading

References

Aug 5, 2005·The New England Journal of Medicine·Lars Osterberg, Terrence Blaschke
Feb 2, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joyce A CramerPeter K Wong
Feb 20, 2008·Annals of Internal Medicine·Chi Pang WenWen-Shen Isabella Chung
Aug 30, 2008·Hypertension·Joseph T FlynnUNKNOWN Chronic Kidney Disease in Children Study Group
Jan 3, 2009·Paediatrics & Child Health·Danielle TaddeoJean-Yves Frappier
Oct 23, 2009·The New England Journal of Medicine·Elke WühlFranz Schaefer
Jan 22, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Nicholas J A WebbGilbert W Gleim
Aug 16, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Susan L FurthBradley A Warady
Sep 22, 2011·ClinicoEconomics and Outcomes Research : CEOR·Luca Degli EspostiEzio Degli Esposti
May 24, 2012·Journal of the American Pharmacists Association : JAPhA·Sarah L CutronaWilliam H Shrank
Jun 29, 2012·Kidney International·Nicholas J A WebbChun Lam
Nov 23, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Tom D Blydt-HansenSusan L Furth
May 29, 2014·British Journal of Clinical Pharmacology·Asia N RashedIan C K Wong
Jun 21, 2014·The Journal of Pediatrics·Natalie Walders-AbramsonUNKNOWN Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group
Jun 28, 2014·Clinical Journal of the American Society of Nephrology : CJASN·Oleh M AkchurinAmy L Skversky
Oct 23, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Elvira O Gosmanova, Csaba P Kovesdy
Oct 30, 2014·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Norkasihan IbrahimYogini Jani
Apr 17, 2015·Pediatric Transplantation·Kristin A LoiselleRonald L Blount
Feb 7, 2016·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Hsin-Hsu ChouYuan-Yow Chiou
Jan 1, 2015·Clinical Hypertension·Noah JarariLaxmi Teja Peela
Nov 9, 2016·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Alison G AbrahamAlvaro Muñoz

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.